Literature DB >> 22496710

Optimizing the management of benign prostatic hyperplasia.

Dean S Elterman, Jack Barkin, Steven A Kaplan.   

Abstract

One of the challenges facing primary care physicians and specialists as the population ages is the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). While as many as 18% of men in their 40s report bother from an enlarged prostate, that figure rises dramatically, whereby 50% of men in their 50s and 90% of men in their 90s will complain of bothersome symptoms related to an enlarged prostate. Studies have shown that BPH is a progressive disease, which if left untreated can result in worsening of symptoms, acute urinary retention and renal failure. Until about 20 years ago the only management option available to urologists was surgery. In the early 1990s medical therapy emerged as the predominant treatment for BPH. Therapy may be tailored to target symptoms and progression of disease.

Entities:  

Keywords:  5-alpha-reducinhibitors; LUTS; alpha-blockers; anticholinergics; benign prostatic hyperplasia

Year:  2012        PMID: 22496710      PMCID: PMC3317543          DOI: 10.1177/1756287212437361

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  29 in total

Review 1.  Natural history of benign prostatic hyperplasia.

Authors:  S J Jacobsen; C J Girman; M M Lieber
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

2.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

3.  Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Steven A Kaplan; Konstantin Walmsley; Alexis E Te
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

Review 4.  Antimuscarinic mechanisms and the overactive detrusor: an update.

Authors:  Karl-Erik Andersson
Journal:  Eur Urol       Date:  2010-12-08       Impact factor: 20.096

5.  Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings.

Authors:  M J Hyman; A Groutz; J G Blaivas
Journal:  J Urol       Date:  2001-08       Impact factor: 7.450

6.  Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

Authors:  Henry H Woo; Peter T Chin; Thomas A McNicholas; Harcharan S Gill; Mark K Plante; Reginald C Bruskewitz; Claus G Roehrborn
Journal:  BJU Int       Date:  2011-05-06       Impact factor: 5.588

7.  Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.

Authors:  Craig F Donatucci; Gerald B Brock; Evan R Goldfischer; Peter J Pommerville; Albert Elion-Mboussa; Jay D Kissel; Lars Viktrup
Journal:  BJU Int       Date:  2011-01-18       Impact factor: 5.588

8.  Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.

Authors:  Jack Barkin; Claus G Roehrborn; Paul Siami; Olivier Haillot; Betsy Morrill; Libby Black; Francesco Montorsi
Journal:  BJU Int       Date:  2009-02-23       Impact factor: 5.588

9.  Evaluation and treatment of lower urinary tract symptoms in older men.

Authors:  P Abrams; C Chapple; S Khoury; C Roehrborn; J de la Rosette
Journal:  J Urol       Date:  2009-02-23       Impact factor: 7.450

10.  Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.

Authors:  Ji Youl Lee; Hyun Woo Kim; Seung Ju Lee; Jun Sung Koh; Hong Jin Suh; Michael B Chancellor
Journal:  BJU Int       Date:  2004-10       Impact factor: 5.588

View more
  5 in total

1.  Cranberry fruit powder (Flowens™) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study.

Authors:  Ales Vidlar; Vladimir Student; Jitka Vostalova; Emilie Fromentin; Marc Roller; Vilím Simanek; Vladimir Student
Journal:  World J Urol       Date:  2015-06-07       Impact factor: 4.226

2.  Life-threatening urethral hemorrhage after placement of a Foley catheter in a patient with uroseptic disseminated intravascular coagulation due to chronic urinary retention induced by untreated benign prostatic hyperplasia.

Authors:  Yukihiro Ikegami; Keisuke Yoshida; Tsuyoshi Imaizumi; Tsuyoshi Isosu; Shin Kurosawa; Masahiro Murakawa
Journal:  Acute Med Surg       Date:  2016-05-03

Review 3.  [Combination therapy of benign prostate syndrome/lower urinary tract symptoms].

Authors:  S Madersbacher
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

4.  Clinical Efficacy of Transurethral Resection of the Prostate Combined with Oral Anticholinergics or Botulinum Toxin - A Injection to Treat Benign Prostatic Hyperplasia with Overactive Bladder: A Case-Control Study.

Authors:  Farzad Allameh; Abbas Basiri; Mohammadreza Razzaghi; Amir Reza Abedi; Morteza Fallah-Karkan; Saleh Ghiasy; Seyyed Mohammad Hosseininia; Saeed Montazeri
Journal:  Clin Pharmacol       Date:  2020-06-26

5.  Development of an online personalized self-management intervention for men with uncomplicated LUTS.

Authors:  Marco H Blanker; Pim Brandenbarg; Bart G C Slijkhuis; Martijn G Steffens; Michael R van Balken; Petra Jellema
Journal:  Neurourol Urodyn       Date:  2019-05-20       Impact factor: 2.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.